PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
READ SAFETY DIRECTIONS BEFORE OPENING OR USING

Vetmedin® 3.5 mg/mL Oral Solution for Dogs

Boehringer Ingelheim

3.5 mg/mL pimobendan

Indications

Vetmedin® 3.5 mg/mL Oral Solution for Dogs is indicated for:

The treatment of canine congestive heart failure (CHF) originating from dilated cardiomyopathy (DCM) or valvular insufficiency (mitral and/or tricuspid regurgitation).

The treatment of preclinical DCM in large breed dogs. When used in case of preclinical DCM in large breed dogs, pimobendan significantly prolonged the time to the onset of CHF or sudden death, and also resulted in prolongation of the time to death due to all causes.

Doberman Pinscher dogs with preclinical DCM treated with pimobendan also demonstrated a significant reduction in left ventricular internal diameter in both systole and diastole (LVIDs/d) in response to therapy.

Net contents

21 mL, 42 mL, or 168 mL

DIRECTIONS FOR USE

Contraindications

This product is contraindicated in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not recommended for functional or anatomical reasons (e.g. aortic stenosis).

Precautions

Vetmedin® 3.5 mg/mL Oral Solution for Dogs should only be administered to pregnant and lactating bitches if the expected therapeutic benefits overweigh the potential risk.

Studies into the effect of pimobendan on the reproductive function of male dogs have not been conducted.

The use in dogs not showing signs of cardiac disease is not recommended.

In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β–antagonist propranolol.

Side effects

A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and can be avoided by reducing the dose in those cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.

Dosage and Administration

Use the contents within three months of first opening. Discard the unused portion.

Vetmedin® 3.5 mg/mL Oral Solution for Dogs should be administered orally at a dose range of 0.1 mg to 0.3 mg pimobendan/kg bodyweight twice daily. The ideal dose is 0.25 mg pimobendan/kg bodyweight (equivalent to 0.07 mL Vetmedin® Oral Solution/kg bodyweight) twice daily administered approximately 12 hours apart. Each dose should be given on an empty stomach, and at least one hour before feeding.

Advice on correct administration

1. Unscrew bottle top and attach the dosing syringe to the bottle by gently pushing the end onto the top of the bottle. Do not force the syringe onto the bottle as this makes it difficult to remove.



2. Turn the bottle/syringe upside down. Pull the plunger out until the black line on the plunger corresponds to your dog's bodyweight in kilograms.



3. Turn the bottle right way up and with a twisting movement gently separate the dosing syringe from the bottle.

4. Gently place the syringe in the mouth of the patient and administer the dose by pressing the plunger until the contents of the syringe are expelled.

General directions

Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.

Vetmedin® 3.5 mg/mL Oral Solution for Dogs may be given concurrently with a diuretic treatment such as furosemide.

In the case of overdosing, symptomatic treatment should be initiated.

Action:

Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity.

Following oral administration of pimobendan the absolute bioavailability of the active principle is 60-63%. The mean plasma protein binding is 93%. The plasma elimination half-life of pimobendan is approximately 30 minutes and the main active metabolite elimination half-life is approximately 2 hours. Almost the entire dose is eliminated via faeces.

Use during pregnancy and lactation:

In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk.

SAFETY DIRECTIONS
Wash hands after use.

FIRST AID
If poisoning occurs contact a doctor or Poisons Information Centre. Phone Australia 131126.

Disposal
Dispose of empty container by wrapping with paper and putting in garbage.

Storage
Store below 25°C (air conditioning). Protect from light.

APVMA 81552/103342

Boehringer Ingelheim Pty Limited
Animal Health Division
78 Waterloo Road
North Ryde NSW 2113
Phone: 1800 038 037
www.boehringer-ingelheim.com.au

Made in Australia

V 20237/AU/1